Background
==========

Identification of the mechanisms of autoimmune inflammatory disease development in the gastrointestinal tract is an emerging topic of research. Inflammatory bowel disease (IBD) is thought to result from immune-mediated tissue injury, primed by the enteric microflora, in genetically predisposed subjects. IBD phenotypically occurs in the form of Crohn\'s disease (CD) or ulcerative colitis (UC). In these disorders, chronic mucosal inflammation results from inappropriate and overreactive mucosal response to intestinal bacteria followed by activation of inflammatory cells and production of inflammatory mediators \[[@B1]\]. Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the hepatic bile ducts that likely develops as a result of an inappropriate immune mediated process \[[@B2]\]. Nearly 80% of northern European PSC patients also have concomitant IBD, mostly in the form of UC \[[@B3]\]. Primary biliary cirrhosis (PBC) is another autoimmune chronic cholestatic liver disorder that may also develop as a result of an abnormal immune response to stimulating environmental or infectious agents \[[@B4]\].

As in other autoimmune diseases, the specific alleles of the human leukocyte antigen (HLA) complex represent genes associated with susceptibility to PSC \[[@B5]-[@B7]\], PBC \[[@B8],[@B9]\] and IBD \[[@B10]\]. It has been reported that the genetic predisposition to CD is caused by alterations in several genes, including *NOD2/CARD15, OCTN1*, *OCTN2*, *DLG*, *ATG16L1*and *IL23R*\[[@B11]-[@B14]\]. Several other non-HLA genes are also involved in PCS and PBC disease susceptibility \[[@B7],[@B15]\].

According to our current understanding of CD, PSC and PBC are complex diseases in which the genetic determinants contributing to disease susceptibility interact with environmental factors. However, the mechanisms underlying these interactions remain unclear. Considering high frequency at which IBD and PSC are diagnosed together \[[@B3]\], close spatial proximity of affected organs, and the fact that common immune mediated processes are likely involved in development of these diseases \[[@B16]\], searching for common risk alleles for IBD and autoimmune cholestatic liver disorders seems to be relevant

Most of the susceptibility genes are considered to not be directly involved in disease pathogenesis, but rather act as environmental response modifiers. Given their subtle individual impact on disease susceptibility, independently they may have little to no effect on disease progression and likely act in collaboration with other factors to promote disease development. Moreover, disease genetic markers vary among the populations studied, despite the phenotypic similarity of disease. Thus, analyzing the genetic background of disease is an important challenge, and several studies have been performed with the purpose of finding similarities in the molecular mechanism of development of different inflammatory disorders of the alimentary tract. The aim of this study was to investigate whether polymorphisms of CD susceptibility genes are predisposing factors to the development of PSC and PBC in a group of Polish patients.

Methods
=======

Patients
--------

The study included 60 patients with CD (28 men, range of 22 -- 78 years old; median 39), 77 patients with PSC (45 men, range of 20 -- 68 years old; median 33), of which 61 exhibited IBD as confirmed by endoscopy and histology (40 UC, 8 CD, and 13 indeterminate colitis), and 144 patients with PBC (8 men, range of 40 -- 72 years old; median 58). All patients were diagnosed at the Department of Gastroenterology and Hepatology, Medical Center for Postgraduate Education and Cancer Center, Warsaw, Poland. Diagnosis of CD was based on generally accepted clinical, endoscopical and histological criteria. The diagnosis of PSC was based on characteristic biochemical and radiological features (irregularity of the intrahepatic and extrahepatic bile ducts in endoscopic retrograde or magnetic resonance cholangiopancreatography). PBC was diagnosed based on generally accepted clinical, biochemical, serological (antimitochondrial antibody positivity by indirect immunofluorescence) and histological findings \[[@B17]\].

The control group consisted of 139 healthy volunteers (74 men, range of 21 -- 66 years old, median 32) recruited from hospital staff, medical students, and healthy subjects selected for screening colonoscopy. All patients and controls were Polish Caucasians. The study was approved by the local ethics committee (Medical Center for Postgraduate Education and Cancer Center, Warsaw, Poland), and all the participants provided appropriate consent. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

Genotyping
----------

Genomic DNA was extracted from whole blood treated with EDTA using the NucleoSpin Blood Quick Pure kit (Macherey-Nagel, Germany), following the manufacturer\'s protocol.

The selected polymorphisms of genes with previously confirmed evidence for association with CD were as follows: *NOD2/CARD15*: rs2066842 (Pro268Ser), rs2066844 (Arg702Trp), rs2066845 (Gly908Arg), rs5743293 (1007fs); in the *SLC22A4/OCTN1*/*SLC22A5/OCTN2*genes: rs1050152 (Leu503Phe)/rs2631367 (-207G\>C); in the *DLG5*gene: rs1248696 (Arg30Gln); in the *ATG16L1*gene: rs2241880 (Thr300Ala); and in the *IL23R*gene: rs11209026 (Arg381Gln), rs1884444 (His3Gln), rs10889677 (exon-3\'UTR).

Genotyping was carried out using TaqMan SNP Genotyping Assays (Applied Biosystems; Foster City, CA). The PCR reactions were performed in 96-well plates on the ABI PRISM 7000 Sequence Detection System (SDS) (Applied Biosystems; Foster City, CA). Each well contained 20 ng genomic DNA, 1.25 μL TaqMan SNP Genotyping Assay (probes and primers mix), 12.5 μL TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems; Foster City, CA), and 9.25 μL water. Two non-template-control wells were included on each plate. After DNA amplification (95°C for 10 min, followed by 40 cycles of 92°C for 15 sec and 60°C for 1 min), fluorescence was acquired and analyzed for allelic discrimination using the ABI Prism 7000 SDS Software.

Statistical analyses
--------------------

The frequency distribution of alleles, genotypes, and haplotypes was compared using standard or Yates corrected χ^2^test and Fisher\'s exact test when appropriate. Statistical significance threshold level was Bonferroni corrected for multiple hypothesis testing, according to the number of genes tested. The p-value significance threshold level was defined as 0.008. For the Fisher\'s exact tests, the STATISTICA software was used. ORs with 95% confidence intervals (95% CI) were calculated using a calculator available at <http://www.hutchon.net/ConfidOR.htm>. LD analysis and calculation of the Hardy-Weinberg equilibrium were performed using the Haploview v3.2 software, available at <http://www.broad.mit.edu/mpg/haploview/>. Statistical power analyses were done using G\*power\'s (ver. 3.0.10) \[[@B18]\] post-hoc procedure for the Fisher\'s exact test.

Results and Discussion
======================

Allelic distributions for all polymorphisms studied in the patient and control groups are shown in Table [1](#T1){ref-type="table"}, while genotype counts for each of the studied groups are presented in Additional file [1](#S1){ref-type="supplementary-material"} \[see Additional file [1](#S1){ref-type="supplementary-material"}\]. In the control group, the genotype distributions for all polymorphisms were in Hardy-Weinberg equilibrium (p \> 0.05).

###### 

Allelic distribution in patients and healthy controls for all polymorphisms

  Polymorphism            Genotype   CD     PSC    PBC    Controls
  ----------------------- ---------- ------ ------ ------ ----------
  NOD2/CARD15 Pro268Ser   C/C        0.33   0.48   0.58   0.56
                          C/T        0.40   0.45   0.36   0,41
                          T/T        0.27   0.06   0.06   0.03
  NOD2/CARD15 Arg702Trp   C/C        0.83   0.92   0.93   0.97
                          C/T        0.17   0.08   0.07   0.03
                          T/T        0.00   0.00   0.00   0.00
  NOD2/CARD15 Gly908Arg   G/G        0.95   0.96   0.97   0.94
                          G/C        0.05   0.04   0.03   0.06
                          C/C        0.00   0.00   0.00   0.00
  NOD2/CARD15 1007fs      -/-        0.63   0.91   0.92   0.94
                          -/C        0.27   0.08   0.08   0.06
                          C/C        0.10   0.01   0.00   0.00
  OCTN1 Leu503Phe         C/C        0.27   0.35   0.37   0.37
                          C/T        0.50   0.52   0.43   0.46
                          T/T        0.23   0.13   0.20   0.17
  OCTN2-207G\>C           G/G        0.25   0.28   0.30   0.27
                          G/C        0.47   0.54   0.43   0.46
                          C/C        0.27   0.18   0.27   0.27
  DLG5 Arg30Gln           C/C        0.80   0.77   0.82   0.80
                          C/T        0.18   0.21   0.17   0.19
                          T/T        0.02   0.03   0.01   0.01
  IL23R Arg381Gln         G/G        0.97   0.90   0.92   0.95
                          G/A        0.03   0.09   0.08   0.05
                          A/A        0.00   0.01   0.00   0.00
  IL23R His3Gln           C/C        0.19   0.26   0.23   0.30
                          C/A        0.59   0.57   0.54   0.49
                          A/A        0,22   0.17   0.23   0.22
  IL23R exon-3\'UTR       C/C        0.40   0.53   0.51   0.49
                          C/A        0.52   0.41   0.40   0.42
                          A/A        0.08   0.07   0.08   0.09
  ATG16L1 Thr300Ala       C/C        0.39   0.29   0.25   0.23
                          C/T        0.42   0.51   0.52   0.50
                          T/T        0.19   0.20   0.23   0.27

The *Caspase Recruitment Activation Domain 15*(*NOD2/CARD15*) gene is located in the proximal region of chromosome 16 (16q12) and encodes the nucleotide-binding oligomerization domain protein 2 (NOD2), which is a cytosolic receptor for a bacterial peptidoglycan response pathway \[[@B19]\]. Mutations in NOD2 result in immune system dysfunctions \[[@B11],[@B20]\] and are considered causative genetic factors in the development of CD. *NOD2/CARD15*mutations are also associated with susceptibility to other granulomatous inflammatory disorders, such as early-onset sarcoidosis and Blau syndrome \[[@B21],[@B22]\].

Three of the four *NOD2/CARD15*variants tested (rs2066842, rs2066844, rs5743293) were strongly associated with CD (Table [2](#T2){ref-type="table"}). In particular, a strong association was observed with Pro268Ser and 1007fs SNPs with odds ratio (OR) values over 10. Increased values of OR for homozygous risk genotypes confirm previously described codominance of these variants. The observed allele distribution was similar to those reported in other Caucasian CD patient groups \[[@B23]-[@B25]\].

###### 

Statistical analyses for significant genotype associations

  ----------------------------------------------------------------------------------------------------
  Patient group   SNP           Genotype    OR         95% CI   p-value          Stat.\        
                                                                                 Power         
  --------------- ------------- ----------- ---------- -------- ---------------- ------------- -------
  Crohn\'s\       NOD2/CARD15   Pro268Ser   C/T+T/T\   2.52\    1.34 -- 4.75\    0.005\        0.59\
  disease                                   T/T        12.18    3.86 -- 38.37    0.0000003     0.98

                  NOD2/CARD15   Arg702Trp   C/T+T/T\   6.65\    1.99 -- 22.17\   0.0013\       0.71\
                                            T/T        n/a      n/a              n/a           n/a

                  NOD2/CARD15   1007fs      -/C+C/C\   9.59\    3.94 -- 23.29\   0.00000002\   0.99\
                                            C/C        \>16     \-\--            0.0006        0.86

                  ATG16L1       Thr300Ala   T/C+T/T\   0.468\   0.24 -- 0.90\    0.022\        0.32\
                                            T/T        0.632    0.30 -- 1.34     0.231         0.05
  ----------------------------------------------------------------------------------------------------

*The autophagy-related 16-like 1*(*ATG16L1*) gene encodes the protein component of the autophagosome pathway of intracellular bacteria processing. The T300A variant (rs2241880) was previously considered to be a risk factor for CD development \[[@B26],[@B27]\]. In our CD patients, however, this variant demonstrated only a weak associaf2tion with CD, as the p-value (= 0.022) did not pass the Bonferroni corrected significance threshold level of 0.008.

The organic cation transporters from the family of solute carrier protein (*SLC22A4/OCTN1*and *SLC22A5/OCTN2*) genes are located on chromosome 5 (5q31) within the IBD5 region \[[@B28]\]. The 1672C/T (Leu503Phe) missense variant of *SLC22A4/OCTN1*(rs1050152) potentially alters the carnitine adsorption and the exchange of other positively charged compounds between the cell and extracellular matrix \[[@B29]\]. Also included in this study is the G-to-C transversion in the *SLC22A5/OCTN2*promoter (rs2631367), which is thought to affect a heat shock transcription factor binding element \[[@B30]\]. The variants of both genes were previously found in linkage disequilibrium, enabling the selection of a two-allele CD risk haplotype \[[@B28],[@B31]\]. This finding, however, has not been confirmed by other studies \[[@B29]\].

As shown in Table [3](#T3){ref-type="table"}, there was a weak association between the protective *OCTN1/OCTN2*CC haplotype and CD (OR = 0.28; CI = 0.08 -- 0.94; p = 0.0298). A strong linkage disequilibrium was found between the *NOD2/CARD15*Pro268Ser loci and three other studied loci of *NOD2/CARD15*. Analyses of reconstructed haplotypes for each patient group showed that the odds of TC haplotype of Pro268Ser and 1007fs loci is approximately ten times higher (OR = 10.26; CI = 4.52 -- 23.29; p = 0.0000000000671) among patients with CD compared to healthy controls.

###### 

Statistical analyses using Haploview software (ver. 3.2) for significant haplotype associations.

  Patient group      SNP                               Haplotype   OR      95% CI          p-value
  ------------------ --------------------------------- ----------- ------- --------------- -----------------
  Crohn\'s disease   NOD2/CARD15 Pro268Ser/Arg702Trp   TC          2.25    1.41 -- 3.58    0.0005
                     NOD2/CARD15 Pro268Ser/Gly908Arg   TG          3.01    1.89 -- 4.78    0.000002
                     NOD2/CARD15 Pro268Ser/1007fs      TC          10.26   4.52 -- 23.29   0.0000000000671
                     OCTN1/OCTN2                       CC          0.28    0.08 -- 0.94    0.0298

The *interleukine-23 receptor*(*IL23R*) gene is located on chromosome region 1p31, and encodes a subunit of the IL23 receptor. IL23 and IL6 activate the STAT3 transcription factor which in turn leads to differentiation of CD4+ helper T cells into Th17 cells that function in driving autoimmune inflammation by producing pro-inflammatory cytokines, such as IL-17A, IL-17F and IL-22 \[[@B13],[@B32]-[@B35]\]. Genetic variants of *IL23R*were identified as disease-associated factors in chronic inflammatory disorders, such as IBD \[[@B12]\], psoriasis, T-cell-mediated inflammatory disease of the skin \[[@B36]\], and ankylosing spondylitis \[[@B37]\], indicating the involvement of the IL23/IL23R pathway in the etiology of various autoimmune-related disorders. Several genetic non-coding variants of this gene demonstrated independent risk association with CD, while the rare variant in the coding region of *IL23R*(1142G/A; Arg381Gln; rs11209026) has been regarded as a CD protective variant \[[@B12],[@B13]\].

We did not find any association of CD not only with Arg381Gln, but also two other more frequent variants of *IL23R*. The frequency of the G/A genotype of rs11209026 SNP was 3.3% in CD (2 of 60) compared to 5.8% (8 of 139) in controls, and only one of the patients and controls was homozygous for the AA genotype (not significant). Thus, although this rare variant was found at a similar proportion to that described from the genome-wide scan-based population studies (2.5--3.0% *versus*6.2--6.8%; \[[@B13],[@B38]\]), our small group of CD patients (N = 60) was insufficient to reach statistical significance for this disproportion.

The *Drosophila*disc large homolog 5 (*DLG5*) gene, mapped to chromosome 10 (10q23), is a member of the membrane-associated guanylate kinase gene family \[[@B10],[@B39]\] and encodes a protein involved in maintaining the correct shape, polarity and growth of cells. The functional variant (113G/A, Arg30Gln, rs1248696) has been proposed to potentially lead to serious abnormalities in both the structure and function of cells. Although the first study of Stoll *et al.*\[[@B40]\] reported an association between genetic variants in *DLG5*and IBD, the more recent meta-analysis of published data on Arg30Gln question this association \[[@B10]\]. Our study did not show any association between the Arg30Gln variant of *DLG5*and CD.

In contrast to CD patients, none of the polymorphisms showed association with PSC and PBC, two disorders of autoimmune etiology. Furthermore, no significant associations were detected in PSC patients with concurrent IBD. These negative results are consistent with the recently published studies in Scandinavian PSC patients, the largest PSC population in which genotyping has been performed \[[@B2]\], and in a group of Hungarian and Polish patients with PBC \[[@B41]\].

The present study confirms a strong association of *NOD2/CARD15*gene variants, and to a lesser extent the coding *ATG16L1*variant and the *OCTN1/OCTN2*haplotype, with CD in a relatively small Polish Caucasian patient group. There was no evidence for significant association between variants of *IL23R*or *DLG5*and CD. However, because small sample size significantly limits estimation of genetic variant disproportion, especially with a low prevalence of allelic frequency, whether the result represents a true negative association or a false negative finding is somewhat disputable, mainly due to insufficient power of statistical tests \[[@B7]\]. In fact, calculation of the statistical testing power reached decent values only for the three main *NOD2/CARD15*variants (Table [4](#T4){ref-type="table"}). Therefore, considering SNP frequencies, small patient groups and measured effect size, our studies might not be able to confirm existing weak and even moderate disease associations.

###### 

Power of genotype association statistics given as 1-β error probability. The β represents the probability of falsely accepting H0 hypothesis (lack of association) when in fact H1 hypothesis (association) is true.

  Polymorphism            Genet. model   CD       PSC      PBC
  ----------------------- -------------- -------- -------- --------
  NOD2/CARD15 Pro268Ser   dominant       0.59     0.04     \<0.01
                          recessive      0.98     0.03     0.04
  NOD2/CARD15 Arg702Trp   dominant       0.71     0.11     0.08
                          recessive      n/a      \<0.01   n/a
  NOD2/CARD15 Gly908Arg   dominant       \<0.01   \<0.01   0.05
                          recessive      n/a      n/a      n/a
  NOD2/CARD15 1007fs      dominant       0.99     0.02     0.01
                          recessive      0.86     \<0.01   n/a
  OCTN1 Leu503Phe         dominant       0.08     \<0.01   \<0.01
                          recessive      0.04     0.02     0.02
  OCTN2-207G\>C           dominant       \<0.01   \<0.01   0.01
                          recessive      \<0.01   0.09     \<0.01
  DLG5 Arg30Gln           dominant       \<0.01   0.02     0.01
                          recessive      \<0.01   0.02     \<0.01
  IL23R Arg381Gln         dominant       \<0.01   0.08     0.03
                          recessive      \<0.01   \<0.01   n/a
  IL23R His3Gln           dominant       0.09     0.01     0.06
                          recessive      \<0.01   0.02     \<0.01
  IL23R exon-3\'UTR       dominant       0.05     0.01     0.01
                          recessive      \<0.01   0.01     \<0.01
  ATG16L1 Thr300Ala       dominant       0.32     0.04     0.01
                          recessive      0.05     0.04     0.02

Conclusion
==========

Although inappropriate immune mediated processes are also related with PSC and PBC, this study and previously published \[[@B2],[@B41]\] studies have not identified common allelic variants. In IBD, risk variants of genes encoding proteins that are involved in signalling pathways activated by bacterial products have been described. Consequently, IBD is thought to result from dysfunction of the mucosal immune response triggered by intestinal bacteria, and defects in the early immune response may play a role in the pathogenesis of CD \[[@B1],[@B42],[@B43]\]. However, this hypothesis is based on statistical considerations rather than functional studies. It is noteworthy that only some CD patients carry mutated *NOD2/CARD15*and/or other risk gene variants, and therefore, mechanisms for CD development likely are not simply related to mutations within described risk genes. Furthermore, the genetic background of CD possibly is based on more causative genetic factors than studied thus far, and each of them independently may have a relatively weak impact on disease development.

Such high complexity of disease background requires mapping of genetic predisposition using genome-wide and large-scale studies in well-defined populations. Despite the fact that these kind of studies are still relatively expensive, they are likely the most cost effective giving real capacity to provide comprehensive insight into disease development mechanisms.

Even though familial aggregation is observed in many complex diseases, including IBD, PSC and PBC, genetic factors in complex diseases should be considered as \"risk-factor genes\" rather than genes responsible for the development of a particular disease. Their presence is not synonymous with the development of the disease. Thus, functional studies should be initiated in order to clarify the contribution of genetic background in development of these diseases.
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